'On consolidated basis
Quarter ended December 2024 compared with Quarter ended December 2023.
Net sales (including other operating income) of Lupin has increased 10.97% to Rs 5767.71 crore. Sales of Pharmaceuticals segment has gone up 10.86% to Rs 5,742.04 crore (accounting for 99.54% of total sales). Sales of others segment has gone up 45.81% to Rs 26.29 crore (accounting for 0.46% of total sales). Inter-segment sales rose Rs 0.22 crore to Rs 0.62 crore.
Profit before interest, tax and other unallocable items (PBIT) has jumped 45.53% to Rs 1,071.27 crore. PBIT of Pharmaceuticals segment rose 44.54% to Rs 1,108.47 crore (accounting for 103.47% of total PBIT). PBIT of others segment fell 20.90% to Rs -37.20 crore (accounting for -3.47% of total PBIT).
PBIT margin of Pharmaceuticals segment rose from 14.81% to 19.30%. PBIT margin of others segment rose from ne...
Pleaselogin & subscribe to view the full report.
More Reports
-
-
Revenue up by 3.3% YoY to Rs 4304.7 crore in Q3FY2025
-
-
|
|